Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent must be obtained prior to participation in the study.
Male or female participants 18 to 80 years of age (inclusive) at the screening.
Lp(a) ≥ 150 nmol/L at screening, measured at the central laboratory.
Participants with evidence of atherosclerotic cardiovascular disease and/or type 2 diabetes mellitus.
You may not be if
Severe renal dysfunction
Hepatic dysfunction
Malignancy within the last 5 years
Use of investigational medications as defined in the protocol
History or presence at screening of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the Investigator, or sponsor if consulted, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data
Clareo Health | A Study of DII235 in Adults With Elevated Lipoprotein(a)
